Zhong Lun Advises on Transcenta’s IPO in Hong Kong
Zhong Lun Advises on Transcenta’s IPO in Hong Kong
On September 29, 2021, Transcenta Holding Limited (6628.HK) announced the closing of its initial public offering on the Main Board of the Stock Exchange of Hong Kong Limited, raising the proceeds of approximately HK$645 million prior to the exercise of the over-allotment option. Goldman Sachs and CICC acted as joint sponsors for the offering.
Transcenta is a clinical stage biopharmaceutical company that integrates the capacities of discovery, research & development, manufacturing, and business development. It has developed a unique antibody discovery platform, the Immune Tolerance Breaking Technology Platform (IMTB).
Zhong Lun acted as the issuer’s PRC legal advisor in this offering. The Zhong Lun team was led by Anthony Zhao and William Jia and included Roy Zheng, Lindsay Zhang, etc.; and Lefan Gong advised on the ESOP design during the IPO process.
Professionals
-
-
-
Anthony ZHAO
Equity Partner
Shanghai
-
-
-
-
William JIA
Equity Partner
Shanghai
-
-
-
-
Lefan GONG
Equity Partner
Shanghai
-